Top

Published in:

01-06-2015 | CONTRAST MEDIA

Tissue gadolinium deposition in hepatorenally impaired rats exposed to Gd-EOB-DTPA: evaluation with inductively coupled plasma mass spectrometry (ICP-MS)

Authors: Tomohiro Sato, Tsutomu Tamada, Shigeru Watanabe, Hirotake Nishimura, Akihiko Kanki, Yasufumi Noda, Atsushi Higaki, Akira Yamamoto, Katsuyoshi Ito

Published in: La radiologia medica | Issue 6/2015

Abstract

Purpose

This study was undertaken to quantify tissue gadolinium (Gd) deposition in hepatorenally impaired rats exposed to gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) by means of inductively coupled plasma mass spectrometry (ICP-MS) and to compare differences in Gd distribution among major organs as possible triggers for nephrogenic systemic fibrosis.

Materials and methods

Five hepatorenally impaired rats (5/6-nephrectomized, with carbon-tetrachloride-induced liver fibrosis) were injected with Gd-EOB-DTPA. Histological assessment was conducted and Gd content of the skin, liver, kidneys, lungs, heart, spleen, diaphragm, and femoral muscle was measured by inductively coupled plasma mass spectrometry (ICP-MS) at 7 days after last injection. In addition, five renally impaired rats were injected with Gd-EOB-DTPA and the degree of tissue Gd deposition was compared with that in the hepatorenally impaired rats.

Results

ICP-MS analysis revealed significantly higher Gd deposition in the kidneys, spleen, and liver (p = 0.009–0.047) in the hepatorenally impaired group (42.6 ± 20.1, 17.2 ± 6.1, 8.4 ± 3.2 μg/g, respectively) than in the renally impaired group (17.2 ± 7.7, 5.4 ± 2.1, 2.8 ± 0.7 μg/g, respectively); no significant difference was found for other organs. In the hepatorenally impaired group, Gd was predominantly deposited in the kidneys, followed by the spleen, liver, lungs, skin, heart, diaphragm, and femoral muscle. Histopathological investigation revealed hepatic fibrosis in the hepatorenally impaired group.

Conclusions

Compared with renally impaired rats, tissue Gd deposition in hepatorenally impaired rats exposed to Gd-EOB-DTPA was significantly increased in the kidneys, spleen, and liver, probably due to the impairment of the dual excretion pathways of the urinary and biliary systems.

Cowper SE, Robin HS, Steinberg SM et al (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356:1000–1001CrossRefPubMed

Cowper SE, Su LD, Bhawan J et al (2001) Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23:383–393CrossRefPubMed

Cowper SE (2003) Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 15:785–790CrossRefPubMed

Thomsen HS (2004) Gadolinium-based contrast media may be nephrotoxic even at approved doses. Eur Radiol 14:1654–1656PubMed

Schmook T, Budde K, Ulrich C et al (2005) Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy. Nephrol Dial Transplant 20:220–222CrossRefPubMed

DeHoratius DM, Cowper SE (2006) Nephrogenic systemic fibrosis: an emerging threat among renal patients. Semin Dial 19:191–194CrossRefPubMed

Perazella MA (2007) Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link? Clin J Am Soc Nephrol 2:200–202CrossRefPubMed

Perazella MA, Rodby RA (2007) Gadolinium use in patients with kidney disease: a cause for concern. Semin Dial 20:179–185CrossRefPubMed

Sadowski EA, Bennett LK, Chan MR et al (2007) Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243:148–157CrossRefPubMed

10.

Thomsen HS (2007) European Society of Urogenital Radiology guidelines on contrast media application. Curr Opin Urol 17:70–76CrossRefPubMed

11.

Kanal E, Broome DR, Martin DR et al (2008) Response to the FDA’s May 23, 2007, nephrogenic systemic fibrosis update. Radiology 246:11–14CrossRefPubMed

12.

Prince MR, Zhang H, Morris M et al (2008) Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 248:807–816CrossRefPubMed

13.

Wertman R, Altun E, Martin DR et al (2008) Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 248:799–806CrossRefPubMed

14.

Altun E, Martin DR, Wertman R et al (2009) Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy—report from two US universities. Radiology 253:689–696CrossRefPubMed

15.

Pietsch H, Lengsfeld P, Steger-Hartmann T et al (2009) Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol 44:226–233CrossRefPubMed

16.

Proctor E, Chatamra K (1984) Standardized micronodular cirrhosis in the rat. Eur Surg Res 16:182–186CrossRefPubMed

17.

Knopp MV, Balzer T, Esser M et al (2006) Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use. Invest Radiol 41:491–499CrossRefPubMed

18.

Bourrinet P, Martel E, El Amrani AI et al (2007) Cardiovascular safety of gadoterate meglumine (Gd-DOTA). Invest Radiol 42:63–77CrossRefPubMed

19.

Herborn CU, Honold E, Wolf M et al (2007) Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA). Invest Radiol 42:58–62CrossRefPubMed

20.

Runge VM (2001) Safety of magnetic resonance contrast media. Top Magn Reson Imaging 12:309–314CrossRefPubMed

21.

Sieber MA, Pietsch H, Walter J et al (2008) A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol 43:65–75CrossRefPubMed

22.

Penfield JG, Reilly RF (2008) Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents? Semin Dial 21:129–134CrossRefPubMed

23.

Leiner T, Kucharczyk W (2009) Special issue: nephrogenic systemic fibrosis. J Magn Reson Imaging 30:1233–1235CrossRefPubMed

24.

Thomsen HS (2009) Nephrogenic systemic fibrosis: history and epidemiology. Radiol Clin North Am 47:827–831CrossRefPubMed

25.

Gschwend S, Ebert W, Schultze-Mosgau M et al (2011) Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment. Invest Radiol 46:556–566CrossRefPubMed

26.

Schuhmann-Giampieri G, Frenzel T, Schmitt-Willich H (1993) Pharmacokinetics in rats, dogs and monkeys of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging. Arzneimittelforschung 43:927–931PubMed

27.

Hamm B, Staks T, Muhler A et al (1995) Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195:785–792CrossRefPubMed

28.

Muhler A, Heinzelmann I, Weinmann HJ (1994) Elimination of gadolinium-ethoxybenzyl-DTPA in a rat model of severely impaired liver and kidney excretory function. An experimental study in rats. Invest Radiol 29:213–216CrossRefPubMed

29.

Sato T, Ito K, Tamada T et al (2013) Tissue gadolinium deposition in renally impaired rats exposed to different gadolinium-based MRI contrast agents: evaluation with inductively coupled plasma mass spectrometry (ICP-MS). Magn Reson Imaging 31:1412–1417CrossRefPubMed

30.

Caravan P, Ellison JJ, McMurry TJ et al (1999) Gadolinium (III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 99:2293–2352CrossRefPubMed

31.

Morcos SK (2007) Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Brit J Radiol 80:73–76CrossRefPubMed

32.

Morcos SK (2011) Experimental studies investigating the pathophysiology of nephrogenic systemic fibrosis; what did we learn so far? Eur Radiology 21:496–500CrossRef

33.

Weinmann HJ, Schuhmann-Giampieri G, Schmitt-Willich H et al (1991) A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med 22:233-237; discussion 242

Title: Tissue gadolinium deposition in hepatorenally impaired rats exposed to Gd-EOB-DTPA: evaluation with inductively coupled plasma mass spectrometry (ICP-MS)
Authors: Tomohiro Sato
Tsutomu Tamada
Shigeru Watanabe
Hirotake Nishimura
Akihiko Kanki
Yasufumi Noda
Atsushi Higaki
Akira Yamamoto
Katsuyoshi Ito
Publication date: 01-06-2015
Publisher: Springer Milan
Published in: La radiologia medica / Issue 6/2015
Print ISSN: 0033-8362
Electronic ISSN: 1826-6983
DOI: https://doi.org/10.1007/s11547-014-0492-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Tissue gadolinium deposition in hepatorenally impaired rats exposed to Gd-EOB-DTPA: evaluation with inductively coupled plasma mass spectrometry (ICP-MS)

Abstract

Purpose

Materials and methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2015

Clinical outcome of percutaneous RF-ablation of non-operable patients with liver metastasis from breast cancer

Secondary prevention at 360°: the important role of diagnostic imaging

Fluoroscopy-guided hydrostatic reduction of intussusception in infancy: role of pharmacological premedication

Diffusion-weighted magnetic resonance imaging for predicting and detecting the response of ocular melanoma to proton beam therapy: initial results

Test–retest reliability of diffusion tensor imaging of the liver at 3.0 T

RIS-PACS, patient safety, and clinical risk management